Navigation Links
Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
Date:7/28/2014

IS-SC1 study.  Enrolled patient demographics and disease characteristics for the CHABLIS-SC1 study are consistent with our goal to enroll patients with higher levels of lupus activity and positive biomarkers despite the stable use of corticosteroids.  These characteristics appeared predictive of improved outcomes in our previous Phase 2 clinical study.  Additional information and publications from the CHABLIS-SC1 clinical study can be found at http://www.anthera.com/studies_chablis-sc1.htm.

We have submitted the final protocol to the US FDA for our second lupus registration study, CHABLIS-SC2. This second study is expected to enroll up to 400 patients with active lupus, including patients with glomerulonephritis who may have a previous diagnosis of Lupus Nephritis.  Consistent with the CHABLIS-SC1 clinical study, the primary endpoint of this second study will be the SRI-8 response. These two pivotal studies will form the basis of a submission for blisibimod as a treatment for patients with active lupus.

Blisibimod for the treatment of IgA Nephropathy (BRIGHT-SC)

The BRIGHT-SC clinical study is currently recruiting patients with a biopsy-proven diagnosis of IgA nephropathy in seven countries in Southeast Asia. We have begun expansion of the BRIGHT-SC study's footprint in Europe, Canada and Japan and expect to enroll patients in the new geographies in the fourth quarter of 2014.  It is our plan to conduct an interim analysis to determine the effect of blisibimod on proteinuria after eight weeks of treatment in the second half of 2014.

In April 2014, we met with Japan Pharmaceuticals and Medical Devices Agency ("PMDA") to discuss our registration program with blisibimod in patients with IgA nephropathy.  In this meeting we gained the PMDA's agreement on the acceptability of proteinuria as the primary efficacy endpoint to support marketing approval in
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  For Cloud ... drug design and development, partnering is an integral ... is to design new drugs and identify early ... partners to further their development. The company also ... To support this business model, Cloud Pharmaceuticals will ...
(Date:9/19/2014)... Sept. 19, 2014  Diplomat, the nation,s largest independent ... Dreyer to the Board of Directors on September ... will also serve as chair of the Audit Committee. ... of accounting, financial, compliance and operating experience in the ... served as chief financial officer, chief operating officer and ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... 19, 2011 MMIS , Inc. ... compliance solutions for the life science industry, announced the ... aggregate spend reporting solution, at the ExL Pharma 2nd ... MediSpend™ allows pharmaceutical, medical device and biotechnologies companies to ...
... Health today announced a joint venture with leading China ... to doctors in China as the country prepares for ... Wolters Kluwer Health to expand its market-leading Clinical Decision ... growing China market and creates a needed drug information ...
Cached Medicine Technology:MMIS, Inc. Launches the MediSpend™ Aggregate Spend Solution 2Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom 2Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom 3
(Date:9/19/2014)... 19, 2014 Singulair, developed by Merck, ... of leukotriene D4 (LTD4). LTD4 belongs to the family ... of cells, including mast cells and eosinophils, and which ... have determined that there are higher concentrations of Cys-LTs ... non-asthmatic individuals. The production of CysLTs is increased in ...
(Date:9/19/2014)... University researchers say a simple test that combines ... risk for developing Alzheimer,s disease in a person, ... of dementia., Faculty of Health Professor Lauren Sergio ... study asked the participants to complete four increasingly ... laptop computers. The test aimed at detecting the ...
(Date:9/19/2014)... September 19, 2014 The ... traditional Scandinavian style of eating, is making ... like Diet Doc’s medical weight loss ... and eating good food which leads to ... on teaching patients to understand how diet ...
(Date:9/19/2014)... September 19, 2014 2013 NEXT ... named a finalist for the 2014 NEXT Awards ... president Tammy Hawes has been selected as the ... The Nashville Area Chamber of Commerce and the ... to recognize the accomplishments of companies and individual ...
(Date:9/19/2014)... King of Prussia, PA (PRWEB) September 19, 2014 ... provider of Business Process Outsourcing solutions for Health ... and Managed Medicaid markets, will sponsor a Networking ... Director in the Health Industry Advisory Practice at ... 30, 2014 at the AHIP’s 2014 National Conference ...
Breaking Medicine News(10 mins):Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 2Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 3
... /PRNewswire-FirstCall/ Medizone International,Inc. (Pink Sheets: MZEI) announces ... TDV Global, Inc. (TDVGlobal.com). TDV Global,is a ... Approximately 70% of their business involves consulting ... private enterprise,mostly in the Health and Security ...
... 4 Senesco,Technologies, Inc. ("Senesco" or the "Company") ... will be presenting at the 10th Annual,Rodman & ... the New York,Palace Hotel from November 10-12, 2008. ... will deliver the Company,s corporate,presentation on Tuesday, November ...
... WELLINGTON, Fla., Nov. 4 The Quantum Group,Inc. ... healthcare organization,announced today that Noel J. Guillama, President ... Investment,s 31st Annual Westergaard,Conference on November 12, 2008. ... Vice President and Chief Technology & Innovations Officer,and ...
... and Conference Call ... 8%, HAYWARD, Calif., Nov. 4 Thermage, Inc.,(Nasdaq: ... third quarter,ended September 30, 2008 for both Thermage and ... it may update its Form,S-4 filing with the Securities ...
... connects employers and candidates faster, brings unprecedented functionality and ease of ... ... 4, 2008 -- Dayak, the leading online recruiting marketplace ... easier, and more efficiently, today launched a new version of its ...
... for the Achievement,of Human Potential (IAHP) announced today that ... on The Institutes, world,headquarters in Wyndmoor, Pennsylvania on December ... Child" -- an intensive course covering every,aspect of special ... child who is almost normal but not quite., ...
Cached Medicine News:Health News:Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc. 2Health News:Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference 2Health News:Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference 3Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 2Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 3Health News:Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant 2Health News:Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant 3Health News:Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant 4Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 2Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 3Health News:Parenting Course at The Institutes for the Achievement of Human Potential Gives Parents the Tools to Help their Special Needs Kids Have a Fighting Chance 2
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: